- The Radixact System will be supplied with ClearRT®,
Synchrony®, and the VOLO™ Ultra Optimizer to enhance
radiation treatment delivery precision and speed
- Heidelberg University Hospital is recognized worldwide for
excellence in patient care and practice changing research
MADISON,
Wis., June 27, 2024 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that long-term customer
Heidelberg University Hospital in Heidelberg, Germany, has selected the company's
Radixact® System, equipped with its proprietary
ClearRT®, Synchrony® and VOLO™ Ultra
Optimizer solutions, to help transform their approach to cancer
care. The full-featured system is designed to help provide the
certainty necessary to effectively and efficiently treat the wide
range of cancer cases seen daily in a busy oncology practice. The
Radixact System will replace the older generation Accuray
TomoTherapy® System.
"At Accuray, we understand that certainty matters - to the
clinical teams that use our radiation therapy systems, the patients
who undergo treatment and the families whose loved ones require
care. That's why it's so important to our team to provide customers
around the world with technology that enables them to treat a wider
range of patients and feel confident they are offering the best
possible option for a full, high-quality life," said Suzanne Winter, president and CEO of
Accuray.
Continued Ms. Winter, "We are thrilled to continue our
partnership with the Heidelberg University Hospital team, a global
leader in cancer care. As long-term users of both Accuray
radiotherapy delivery platforms they have a clear understanding of
the value of the helical Radixact/TomoTherapy Systems' and
industry-only robotic, stereotactic CyberKnife® System's
unique designs. We look forward to supporting them as they embark
on the next phase of providing advanced radiotherapy care for their
patients."
Heidelberg University Hospital: Leveraging Advanced Equipment
to Improve the Patient Experience
Heidelberg University
Hospital was an early adopter of image-guided intensity modulated
radiation therapy (IG-IMRT), a targeted form of external beam
radiation therapy that uses images acquired before each treatment
to help ensure accurate patient and tumor positioning before
delivery of the radiation. Two TomoTherapy Systems enabled the
hospital's team to treat up to 100 patients per day while
leveraging the benefits of full image guidance made possible by
IG-IMRT.
The Radixact System integrated with ClearRT helical fan-beam
kVCT imaging, Synchrony motion tracking and synchronization
technology, and VOLO Ultra Optimizer offers an enhanced workflow
along with improved image clarity, enhanced precision, and the
versatility necessary to treat more patients, better and faster.
The hospital joins renowned facilities across the United States, Europe and Asia in adopting the integrated Accuray
solutions.
Heidelberg University Hospital has once again been named one of
the best hospitals in the world in the latest edition of the
"World's Best Hospitals 2024" ranking compiled by Newsweek
magazine. Over their more than 100-year history, the hospital's
center for radiation oncology has become one of the largest and
most modern institutions around the globe, focusing on patient
treatment as well as preclinical cancer research.
Important Safety Information
For Important Safety Information please refer to
https://www.accuray.com/safety-statement.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions designed to deliver radiation
treatments for even the most complex cases—while making commonly
treatable cases even easier—to meet the full spectrum of patient
needs. We are dedicated to continuous innovation in radiation
therapy for oncology, neuro-radiosurgery, and beyond, as we partner
with clinicians and administrators, empowering them to help
patients get back to their lives, faster. Accuray is headquartered
in Madison, Wisconsin, with
facilities worldwide. To learn more, visit www.accuray.com or
follow us on Facebook, LinkedIn, X, and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited to, expectations regarding the
benefits of the company's products to its customers; and patient
experiences and patient outcomes. If any of these risks or
uncertainties materialize, or if any of the company's assumptions
prove incorrect, actual results could differ materially from the
results expressed or implied by these forward-looking statements.
These risks and uncertainties include, but are not limited to, the
company's ability to achieve widespread market acceptance of its
products, including new product innovations and releases; the
company's ability to develop new products or improve existing
products to meet customers' needs; the company's ability to
anticipate or keep pace with changes in the marketplace; the
direction of technological innovation and customer demands and such
other risks identified under the heading "Risk Factors" in the
company's quarterly report on Form 10-Q, filed with the Securities
and Exchange Commission (the "SEC") on May
8, 2024, and as updated periodically with the company's
other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contact
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/heidelberg-university-hospital-in-germany-invests-in-fourth-accuray-radiotherapy-device-the-radixact-system-to-improve-cancer-patient-care-302184128.html
SOURCE Accuray Incorporated